UOC
DYN icon

UBS O'Connor’s Dyne Therapeutics DYN Stock Holding History

UBS O'Connor’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-21,422
Closed -$224K – 407
2025
Q1 		$224K Buy
21,422
+8,838
+70% +$126K 0.01% 246
2024
Q4 		$296K Sell
12,584
-6,734
-35% -$199K 0.01% 312
2024
Q3 		$694K Sell
19,318
-13,626
-41% -$542K 0.02% 316
2024
Q2 		$1.16M Sell
32,944
-181
-0.5% -$5.26K 0.03% 275
2024
Q1 		$940K Sell
33,125
-24,205
-42% -$547K 0.03% 281
2023
Q4 		$762K Sell
57,330
-53,422
-48% -$522K 0.02% 304
2023
Q3 		$992K Sell
110,752
-65,000
-37% -$700K 0.02% 333
2023
Q2 		$1.98M Sell
175,752
-849
-0.5% -$10K 0.04% 295
2023
Q1 		$2.03M Sell
176,601
-31,590
-15% -$410K 0.05% 309
2022
Q4 		$2.41M Buy
208,191
+31,701
+18% +$367K 0.04% 376
2022
Q3 		$2.24M Sell
176,490
-50,868
-22% -$583K 0.03% 611
2022
Q2 		$1.56M Buy
227,358
+102,358
+82% +$705K 0.02% 702
2022
Q1 		$1.21M Buy
+125,000
New +$1.06M 0.01% 669

Other funds holding DYN

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS O'Connor's DYN Position: Q2 2025 in Review

UBS O'Connor sold out of Dyne Therapeutics (DYN) in Q2 2025, closing a stake of 21,422 shares — an estimated $224K sold.

UBS O'Connor first reported a position in DYN in Q1 2022 and held it in 13 quarters. The position peaked at $2.41M in Q4 2022. 197 funds tracked by Wall St. Rank hold DYN as of Q2 2025.

  • UBS O'Connor reported no remaining Dyne Therapeutics position as of Q2 2025 after selling out during the quarter.
  • UBS O'Connor sold 21,422 Dyne Therapeutics shares in Q2 2025, an estimated $224K.
  • UBS O'Connor first reported a position in Dyne Therapeutics in Q1 2022 and held it in 13 quarters.
  • UBS O'Connor's Dyne Therapeutics position peaked at $2.41M in Q4 2022.
  • 197 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2025.

Based on UBS O'Connor's 13F filing for Q2 2025, filed 14 Aug 2025.